Ryan Goetz
Internal Medicine · Birmingham, ALNPI 1063975530
Payments from drug & device makers
Across 70 payments — averaging $68.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AstraZeneca$593
- GSK$465
- Regeneron Healthcare Solutions, Inc.$135
- Sanofi$104
- Takeda Pharmaceuticals U.S.A., Inc.$82
- plus $581 from 16 others
What the payments were for
- Travel & lodging$2265%
- Food & beverage$2,09643%
- Education$2,50052%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $2,863 |
| AstraZeneca | 16 | $593 |
| GSK | 10 | $465 |
| Regeneron Healthcare Solutions, Inc. | 5 | $135 |
| Sanofi | 4 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Merck | 3 | $74 |
| AbbVie | 1 | $66 |
| Mallinckrodt Hospital Products Inc. | 3 | $61 |
| La Jolla Pharmaceutical Company | 2 | $57 |
| Shionogi Inc | 2 | $48 |
| Amgen | 2 | $41 |
| Viatris Specialty LLC | 2 | $40 |
| Verona Pharma, Inc. | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| Grifols USA, LLC | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Electromed, Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Inogen, Inc. | 1 | $15 |
| Pulmonx Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,835
- FASENRA$234
- AREXVY$121
- NUCALA$121
- AIRSUPRA$109
How this compares
$4,823 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 18 | $64,304 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $50,031 |
| Azithromycin | 32 | $380 |
| Pantoprazole Sodium | 26 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $465 | $50,03165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Birmingham
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- William KirbyBirmingham$2.3M
- Jordan VaughnBirmingham$1.6M
- Stefanie KrickBirmingham$527K
- Ryan WeldonBirmingham$458K
- Ashraf KhanBirmingham$215K
- Robert LewisBirmingham$201K
- David WynneBirmingham$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.